Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B

Summary The safety, efficacy, and prolonged half-life of recombinant factor IX Fc fusion protein (rFIXFc) were demonstrated in the Phase 3 B-LONG (adults/adolescents ≥12 years) and Kids B-LONG (children

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis and haemostasis 2017, Vol.117 (3), p.508-518
Hauptverfasser:	Pasi, K.John, Fischer, Kathelijn, Ragni, Margaret, Nolan, Beatrice, Perry, David J., Kulkarni, Roshni, Ozelo, Margareth, Mahlangu, Johnny, Shapiro, Amy D., Baker, Ross I., Bennett, Carolyn M., Barnes, Christopher, Oldenburg, Johannes, Matsushita, Tadashi, Yuan, Huixing, Ramirez-Santiago, Alejandra, Pierce, Glenn F., Allen, Geoffrey, Mei, Baisong
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antibodies, Neutralizing - blood Child Coagulants - administration & dosage Coagulants - adverse effects Coagulation and Fibrinolysis Drug Administration Schedule Factor IX - administration & dosage Factor IX - adverse effects Factor IX - immunology Hemophilia B - blood Hemophilia B - diagnosis Hemophilia B - drug therapy Hemorrhage - blood Hemorrhage - prevention & control Hemostasis - drug effects Humans Immunoglobulin Fc Fragments - administration & dosage Immunoglobulin Fc Fragments - adverse effects Immunoglobulin Fc Fragments - immunology Male Middle Aged Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - immunology Risk Factors Time Factors Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary The safety, efficacy, and prolonged half-life of recombinant factor IX Fc fusion protein (rFIXFc) were demonstrated in the Phase 3 B-LONG (adults/adolescents ≥12 years) and Kids B-LONG (children
ISSN:	0340-6245 2567-689X
DOI:	10.1160/TH16-05-0398